Frontlight ResearchEarly access
CompletedNo phase
Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.
Key facts
- Who runs it
- University Hospital, Bordeaux
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 9 people enrolled
- Started
- 16 Feb 2022
- Ended
- 22 Apr 2024
- Type of study
- Interventional
- Treatments tested
- Piperacillin-tazobactam
- Record updated
- 19 May 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patient above 18 year-old admitted to intensive care unit
- ESBL-E fecal carriage according to current screening recommendations
- Suspicion of ventilator-associated pneumonia according to ICU society guidelines
Who cannot take part
- Known fecal carriage of Carbapenemase-producing Enterobacteriaceae or multi-drug resistant A. baumanii during the past 6 months
- Treatment with piperacillin-tazobactam in the 10 previous days
- Infection with a bacteria resistant to piperacillin-tazobactam during the past 6 months
- Proven hypersensitivity to penicillin or tazobactam
- Neutropenia (neutrophils count < 500/mm3)
- Septic shock according to Sepsis-3 classification
- Pregnancy or breastfeeding
- Curatorship or guardianship
- Prisoners
- No health insurance
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Antimicrobial resistance is a major threat worldwide and now concerns last-ressource antibiotics such as carbapenems. As the resistance to carbapenems is directly due to their use, their spare has become a public health emergency. Their efficacy in ventilator-associated pneumonia has never been compared to other classes of antibiotics such as piperacillin-tazobactam which can be an alternative to carbapenems.
The group in the trial
- InterventionTreatment being tested
The patients included will receive piperacillin-tazobactam as empirical antimicrobial therapy. The empirical microbial therapy will continue until the bacterial susceptibility profile is known.
Treatment: Piperacillin-tazobactam
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Antimicrobial Therapy for Ventilator-associated Pneumonia Among Patients Colonized With Extended-spectrum Beta-lactamase-producing Enterobacteriaceae : Efficacy of a Strategy Using Piperacillin-tazobactam as Empirical Treatment.
- Record updated
- 19 May 2026